PAREXEL International (NASDAQ:PRXL) Ready to Provide Improved Returns

PAREXEL International (NASDAQ:PRXL) has generated a lot more consternation among shareholders than profits, and it seems a growing number are getting even more frustrated over the situation.

Barclays (NYSE:BCS) commented saying, "We recognize some investors might be frustrated that PRXL always appears to be in investment mode. We believe recent share gains by PRXL are the result of long-term investments to build a global infrastructure, offering some vindication for management who bore criticism because these investments suppressed margins below industry norms. Today, margins are being impacted by LEAP, a major operational improvement initiative, and its e-clinical business. Still, PRXL expects to deliver -100 bps of margin improvement while these strategic initiatives are implemented. We think management recognizes the need to strike a balance between solidifying/enhancing PRXL's competitive positioning while also providing evidence of improving returns."

Barclays reiterates their "Overweight" rating on PAREXEL International, which closed Monday at $18.60, gaining $0.33, or 1.81 percent. They have a price target of $25 on them.